Newsroom | 15458 results

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today reported its third quarter 2026 financial results and provided a corporate update. “Strong execution across our business drove another quarter of significant growth, with FILSPARI net product sales of $200 million for the quarter as we continued to expand our reach in IgAN and FSGS,” said Eric Dube, Ph.D., president and chief executive officer of Travere Therapeutics. “We remain early in reaching the more than 100,000 a...

PALO ALTO, Calif.--(BUSINESS WIRE)--Glooko, Inc., a global digital health company focused on helping clinicians address the growing challenges of glycemic safety and diabetes management across the care continuum, today announced the commercial launch of Glooko EndoTool IV Cloud, its FDA 510(k)-cleared, SaaS-based inpatient IV insulin dosing solution. Glooko EndoTool IV Cloud combines EndoTool's established patient-specific clinical intelligence with a modern clinical experience and cloud archite...

CHELMSFORD, Mass.--(BUSINESS WIRE)--ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that PolySense™, a new set of accessories that expands the WatchPAT® 400 from a standard home sleep apnea test (HSAT) to home polysomnography (home PSG), has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). Built from customer feedback, PolySense is designed for simplicity, scalability and speed. Easy self-applied patches...

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Announces Positive Heart Attack Pilot Study Results at TCT 2026: Patient-Recorded 3D ECG Shown to be as Accurate as Standard 12-Lead ECG...

BOSTON--(BUSINESS WIRE)--OM1, Inc., a leader in healthcare AI and real-world data, today announced the posting of a preprint manuscript, Performance of a Foundation Model to Generate Thousands of Predicted Outcomes Across Multiple Use Cases, on the medRxiv preprint server. The paper is the first published performance study of PhenOM®, OM1's generative AI foundation model trained and validated on longitudinal medical histories from more than 400 million de-identified patient records in the OM1 R...

ANN ARBOR, Mich.--(BUSINESS WIRE)--Sling Therapeutics, Inc., a clinical-stage biopharmaceutical company developing the first and only late-stage oral small-molecule therapy for thyroid eye disease (TED), today announced the publication of new preclinical data in the peer-reviewed journal Frontiers in Immunology, highlighting the differentiated mechanism of action of linsitinib and its ability to inhibit key cellular processes involved in the pathogenesis of TED. In addition, Sling announced an u...

BOSTON--(BUSINESS WIRE)--Seaport Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress...

MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for epetraborole in polycythemia vera (PV). The Company has now received regulatory clearance in all planned jurisdictions (A...

RAHWAY, N.J.--(BUSINESS WIRE)--New data include Phase 3 subgroup analyses and patient-reported outcomes of investigational once-weekly oral combination of ISL/LEN....

LONDON & JERSEY CITY, N.J.--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, in partnership with the Depression and Bipolar Support Alliance (DBSA), today released a new report summarizing findings from a national survey of people living with TRD (n=261) and caregivers (n=73) on the self-reported realities of living with a condition that can profoundly affect daily life, revealing th...